Copy
Fostering toxicology across Europe
View this email in your browser

2019 EUROTOX CONGRESS

Register online before August 15, and save €70

 
 
That's right, EUROTOX members and Non-members can save €70 by registering online before August 15. Don't miss the 2019 EUROTOX Helsinki Congress “Toxicology: Science Providing Solutions” taking place September 8-11, 2019. The EUROTOX 2019 congress is one of Europe's most renowned toxicology meeting featuring innovative science lectures and workshops, networking, exhibitors from around the world, and great hospitality in the beautiful city of Helsinki. 

Don't miss the opportunity to register online at the reduced, standard fee. Starting August 16, registration will be possible only onsite. 

CONGRESS HIGHLIGHTS

OPENING KEYNOTE LECTURE

Academician Markku Kulmala, University of Helsinki, a trailblazer in research into ecosystem–atmosphere interactions will open the 2019 EUROTOX Helsinki congress with an exciting keynote lecture "Atmospheric aerosols: from molecular clustering to regional air quality and global climate".

Prof. Kumala is the world’s leading expert in the physics and chemistry of atmospheric aerosols. He conducts research at the forefront of international efforts to significantly increase our understanding of the mechanisms of climate change, creating new opportunities to reduce the pace of climate change and mitigate its effects.

SUNDAY, SEPTEMBER 8 FROM 18.00 TO 19.00
FINLANDIA HALL

 

SATELLITE MEETING


Hazard Identification, Classification and Risk Assessment of Carcinogens: Too Much or Too Little?

There is no cost to attend, but registration is required for this workshop   Registration deadline: August 14, 2019
 
This ECETOC-sponsored workshop is organised around two themes, each of which will have speakers representing different views followed by a panel discussion, with a focus on the path forward:

Theme 1:  Cancer Hazard Identification for Nongenotoxic Substances: Too Much or Too Little ?

Theme 2:  Quantitative Risk Assessment of Nongenotoxic Carcinogens:  Are Current Methods Adequately Protective?


View the entire program here


SUNDAY, SEPTEMBER 8 FROM 09:30 TO 16:00
FINLANDIA HALL

JOB POSTING

Senior Toxicologist, Head of Pharmacology Research in Porto, Portugal (BIAL HQ)


 

Founded in 1924, BIAL’s mission is to discover, develop and provide therapeutic solutions within the area of health. With products available in more than 50 countries throughout four continents BIAL’s commitment is to contribute for the improvement of Human Health and the quality of life of people from all over the world.
 
The selected candidate will be responsible for planning, overseeing, interpreting and reporting non-clinical Safety and Toxicology Studies for our early and late stage portfolio, with a focus on generation of regulatory enabling GLP study packages and contributing to regulatory documentation and interactions.
 
 
Find out more about this exciting opportunity

To apply directly to the BIAL website

EUROTOX NEWS

INAUGURAL MOLECULAR TOXICOLOGY COURSE OFF TO A GREAT START

 
The EUROTOX Molecular Toxicology Specialty Section organised an inaugural course on molecular toxicology at Ege University, Izmir, Turkey, June 26-28. Recent developments in science and feedback from various parties made this educational meeting a much anticipated and well attended event. Izmir hosted 14 invited lecturers a group of 32 course attendees from Algeria, Australia, Belgium, Estonia, Poland, Serbia and Turkey.
 


During the course, PhD students and PhDs from various disciplines tackled contemporary issues in molecular toxicology in an interactive format which allowed the opportunity to discuss scientific topics covered (or not) by the course, as well as share their personal experience. The course was co-financed by EUROTOX.

READ THE COMPLETE REPORT

EU NEWS

Survey into opinions on the studies outlined within ICH S7 guidance. Deadline August 30.

The ICH S7 guidance describes non-clinical safety pharmacology studies as core battery, follow-up or additional studies. The availability of new and evolving technologies, as well as a wish to streamline packages and animal use, has led to many organisations successfully implementing fit-for-purpose testing approaches (for small molecules, biologics and new modalities) which complement the established studies outlined within ICHS7A/B. In order to ascertain how the guidance is used and the relevance of individual studies to current drug development portfolios, the NC3Rs have generated a short survey to gather high-level information on the opinions of individual scientists into the scope for revisiting the guidance.  Survey results will be presented at the Safety Pharmacology Society meeting in September 2019. If you design or run safety pharmacology studies, or use the data to make decisions on drug safety, please follow the link to fill in the online survey:  https://www.surveymonkey.co.uk/r/978KF5B






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
EUROTOX · University of Porto · Department of Biological Sciences · Porto 4050-313 · Portugal

Email Marketing Powered by Mailchimp